These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19226465)

  • 1. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.
    Treur M; Heeg B; Möller HJ; Schmeding A; van Hout B
    BMC Health Serv Res; 2009 Feb; 9():32. PubMed ID: 19226465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
    Laux G; Heeg B; van Hout BA; Mehnert A
    Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
    Haycox A
    Pharmacoeconomics; 2005; 23 Suppl 1():3-16. PubMed ID: 16416758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
    Chue PS; Heeg B; Buskens E; van Hout BA
    Pharmacoeconomics; 2005; 23 Suppl 1():62-74. PubMed ID: 16416762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacoeconomic analysis of compliance gains on antipsychotic medications.
    Damen J; Thuresson PO; Heeg B; Lothgren M
    Appl Health Econ Health Policy; 2008; 6(4):189-97. PubMed ID: 19382819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.
    Godman B; Petzold M; Bennett K; Bennie M; Bucsics A; Finlayson AE; Martin A; Persson M; Piessnegger J; Raschi E; Simoens S; Zara C; Barbui C
    BMC Med; 2014 Jun; 12():98. PubMed ID: 24927744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients' attitudes towards generic substitution of oral atypical antipsychotics: a questionnaire-based survey in a hypothetical pharmacy setting.
    Roman B
    CNS Drugs; 2009 Aug; 23(8):693-701. PubMed ID: 19594198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The introduction of generic risperidone in Medicare Part D.
    Fung V; Price M; Busch AB; Landrum MB; Fireman B; Nierenberg AA; Newhouse JP; Hsu J
    Am J Manag Care; 2016 Jan; 22(1):41-8. PubMed ID: 26799124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
    Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
    J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.
    Bennie M; Bishop I; Godman B; Barbui C; Raschi E; Campbell S; Miranda J; Gustafsson LL
    Int J Clin Pract; 2013 Feb; 67(2):170-80. PubMed ID: 23305478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
    Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D;
    Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
    Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
    J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
    Layton S; Barbeau M
    Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M; Okamoto MP
    J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.
    Einarson TR; Zilbershtein R; Skoupá J; Veselá S; Garg M; Hemels ME
    J Med Econ; 2013 Sep; 16(9):1089-95. PubMed ID: 23808900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.